Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Aug 3;52(9):6133-7.
doi: 10.1167/iovs.11-7419.

How reliable are tests for trachoma?--a latent class approach

Affiliations
Randomized Controlled Trial

How reliable are tests for trachoma?--a latent class approach

Craig W See et al. Invest Ophthalmol Vis Sci. .

Abstract

Purpose: Tests for ocular Chlamydia trachomatis have not been well characterized, because there is no gold standard test. Latent class analysis (LCA) was performed to estimate the sensitivity and specificity of laboratory and clinical tests for trachoma in the absence of a gold standard.

Methods: Individual data from pretreatment, hyperendemic areas in Ethiopia were used. A clustered LCA was performed for three diagnostic tests: PCR and WHO simplified criteria grades of follicular trachoma (TF) and intense trachomatous inflammation (TI).

Results: Data from 2111 subjects in 40 villages were available. TF was estimated to be 87.3% (95% CI, 83.3-90.1) sensitive and 36.6% (95% CI, 23.6-40.3) specific; TI was estimated to be 53.6% (95% CI, 46.1-88.0) sensitive and 88.3% (95% CI, 83.3-92.0) specific, and PCR was estimated to be 87.5% (95% CI, 79.9-97.2) sensitive and 100% (95% CI 69.3-100) specific.

Conclusions: LCA allows for an estimate of test characteristics without prior assumption of their performance. TF and TI were found to act in a complementary manner: TF is a sensitive test and TI is a specific test. PCR is highly specific but lacks sensitivity. The performance of these tests may be due to the time course of ocular chlamydial infection, and for this reason, results may differ in areas of low prevalence or recent mass treatment (ClinicalTrials.gov number, NCT00221364).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Probability density plots of village test prevalence (x-axis) versus relative frequency (y-axis). The figure can be interpreted as a continuous histogram. Distributions for each of the three tests, as well as the latent gold standard (LCA), are shown. Note that the y-axis is dimensionless and that the area under each curve has been normalized.
Figure 2.
Figure 2.
Village-level prevalence of each test for trachoma (y-axis) versus the prevalence of the latent gold standard (LCA, x-axis). Each data point represents the prevalence of positive tests from a single village, with multiple tests from the same village aligned vertically. The diagonal line represents the performance of a perfect test.

Similar articles

Cited by

References

    1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–851 - PMC - PubMed
    1. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet. 1999;354(9179):630–635 - PubMed
    1. Solomon AW, Peeling RW, Foster A, Mabey DCW. Diagnosis and assessment of trachoma (review). Clin Microbiol Rev. 2004;17(4):982–1011 - PMC - PubMed
    1. World Health Organization Report of the Eighth Meeting of the WHO Alliance for the Global Elimination of Blinding Trachoma. Geneva, WHO; 2004
    1. Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med. 1999;5(5):572–576 - PubMed

Publication types

Associated data